Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.74 |
| ▸ | CDK4 | P11802 | 16/20 | 0.74 |
| ▸ | CCND1 | P24385 | 16/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.74 |
| ▸ | CCND3 | P30281 | 3/20 | 0.73 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.73 |
| ▸ | CDK9 | P50750 | 2/20 | 0.73 |
| ▸ | TTK | P33981 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | CCNH | P51946 | 1/20 | 0.61 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.61 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.61 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25948201 | 0.99 | CDK2 (0.75) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948444 | 0.91 | CDK2 (0.72) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL15249270 | 0.91 | CDK2 (0.73) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948177 | 0.91 | CDK2 (0.73) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948095 | 0.89 | CDK2 (0.74) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948076 | 0.89 | CDK2 (0.78) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948187 | 0.88 | CDK4 (0.76) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948150 | 0.88 | CDK2 (0.74) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948161 | 0.88 | CDK2 (0.76) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL25948191 | 0.87 | CDK2 (0.76) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CDK2 69/4885CDK4 16/4885CCND1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.